Published in Int J Radiat Oncol Biol Phys on March 01, 2006
Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer. Radiat Oncol (2014) 0.85
Canadian prostate brachytherapy in 2012. Can Urol Assoc J (2013) 0.82
Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer. Strahlenther Onkol (2012) 0.82
Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review. Radiat Oncol (2015) 0.78
Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality. J Contemp Brachytherapy (2014) 0.78
The use of a memokath prostatic stent for obstructive voiding symptoms after brachytherapy. Curr Urol (2013) 0.77
Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer. J Radiat Res (2014) 0.77
Reduced dose to urethra and rectum with the use of variable needle spacing in prostate brachytherapy: a potential role for robotic technology. J Contemp Brachytherapy (2015) 0.75
Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol. JMIR Res Protoc (2016) 0.75
The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. Brachytherapy (2016) 0.75
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys (2008) 3.65
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer (2009) 2.77
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol (2004) 2.25
PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2004) 2.18
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol (2008) 2.09
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Mechanical ventilation results in progressive contractile dysfunction in the diaphragm. J Appl Physiol (1985) (2002) 1.89
Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys (2002) 1.59
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56
Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. Int J Radiat Oncol Biol Phys (2010) 1.42
Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy (2011) 1.40
Real-time individual predictions of prostate cancer recurrence using joint models. Biometrics (2013) 1.38
Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum (2009) 1.30
A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal high-grade gliomas. Int J Radiat Oncol Biol Phys (2009) 1.25
Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol (2012) 1.21
EUS-guided gold fiducial insertion for image-guided radiation therapy of pancreatic cancer: 50 successful cases without fluoroscopy. Gastrointest Endosc (2010) 1.21
The impact of explicit values clarification exercises in a patient decision aid emerges after the decision is actually made: evidence from a randomized controlled trial. Med Decis Making (2012) 1.21
Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys (2008) 1.19
Evaluation of a cervical cancer screening intervention for prison inmates. Can J Public Health (2004) 1.19
A single set of numerical cutpoints to define moderate and severe symptoms for the Edmonton Symptom Assessment System. J Pain Symptom Manage (2009) 1.18
Diaphragm unloading via controlled mechanical ventilation alters the gene expression profile. Am J Respir Crit Care Med (2005) 1.17
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Eur Urol (2011) 1.16
Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys (2010) 1.15
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer (2012) 1.15
Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys (2003) 1.15
Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol (2013) 1.14
Treatment planning constraints to avoid xerostomia in head-and-neck radiotherapy: an independent test of QUANTEC criteria using a prospectively collected dataset. Int J Radiat Oncol Biol Phys (2011) 1.10
Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment. Am J Clin Oncol (2009) 1.09
Preliminary reliability and validity testing of a new Skin Toxicity Assessment Tool (STAT) in breast cancer patients undergoing radiotherapy. Am J Clin Oncol (2004) 1.07
The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. Can Urol Assoc J (2012) 1.07
Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination. Cancer Causes Control (2009) 1.07
Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? BJU Int (2012) 1.06
Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy. Int J Radiat Oncol Biol Phys (2004) 1.05
Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys (2004) 1.05
Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer (2002) 1.05
In regard to Kupelian et al.: impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. IJROBP 2002;52:704-711. Int J Radiat Oncol Biol Phys (2002) 1.05
Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy. Cancer Metastasis Rev (2014) 1.05
125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. Int J Radiat Oncol Biol Phys (2004) 1.03
Intervention after PSA failure: examination of intervention time and subsequent outcomes from a prospective patient database. Int J Radiat Oncol Biol Phys (2004) 1.03
The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis. Radiother Oncol (2013) 1.01
The self-management of uncertainty among men undertaking active surveillance for low-risk prostate cancer. Qual Health Res (2009) 1.01
Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psychooncology (2010) 1.01
CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate (2014) 1.01
Feasibility study of the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Support Care Cancer (2008) 1.01
Prostate segmentation in 2D ultrasound images using image warping and ellipse fitting. Med Image Comput Comput Assist Interv (2006) 1.00
Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer. J Urol (2003) 1.00
Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. BJU Int (2007) 0.99
Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients. Clin Cancer Res (2009) 0.99
Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J (2012) 0.99
Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting. Can Urol Assoc J (2008) 0.98
Rectal toxicity and rectal dosimetry in low-dose-rate (125)I permanent prostate implants: a long-term study in 1006 patients. Brachytherapy (2011) 0.98
Normal Tissue Complication Probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: A Test of the QUANTEC-recommended NTCP model. Acta Oncol (2010) 0.98
Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys (2010) 0.97
Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys (2009) 0.97
Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists. Can Urol Assoc J (2011) 0.97
Using mixed methods for evaluating an integrative approach to cancer care: a case study. Integr Cancer Ther (2008) 0.95
Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys (2008) 0.95
Patterns of syphilis testing in a large cohort of HIV patients in Ontario, Canada, 2000-2009. BMC Infect Dis (2013) 0.94
Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer (2014) 0.94
Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol (2008) 0.94
Development of indicators of the quality of radiotherapy for localized prostate cancer. Radiother Oncol (2011) 0.93
Three-year follow-up study of women who participated in a cervical cancer screening intervention while in prison. Can J Public Health (2008) 0.93
Impact of providing audiotapes of primary treatment consultations to men with prostate cancer: a multi-site, randomized, controlled trial. Psychooncology (2007) 0.92
Malignant bowel obstruction: natural history of a heterogeneous patient population followed prospectively over two years. J Pain Symptom Manage (2010) 0.91
A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr Cancer (2010) 0.91
Impact of providing audiotapes of primary adjuvant treatment consultations to women with breast cancer: a multisite, randomized, controlled trial. J Clin Oncol (2003) 0.91
Finding needles (or ants) in haystacks: predicting locations of invasive organisms to inform eradication and containment. Ecol Appl (2010) 0.90
Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys (2010) 0.90